T1DM1

T2DM2

Baseline characteristics

N = 26

N = 80

Males, N (%)

11 (42.3)

37 (46.3)

Age (years), mean (SD)

36.5 (13.3)

61.1 (10.9)

Weight (kg), mean (SD)

61.8 (15.9)

63.3 (16.7)

Hb1Ac (%), mean (SD)

9.1 (2.3)

9.0 (1.5)

Duration of diabetes (years), mean (SD)

14.6 (9.3)

16.7 (7.8)

Number of comorbidities, mean (SD)

0.9 (1.0)

2.2 (1.3)

N(%)

Hypertension

Coronary Artery Disease

Myocardial Infarction

Congestive Heart Failure

Stroke

Peripheral Vascular Disease

Dyslipidaemia

Renal Impairment

PCI/CABG

Limp amputation

Dialysis/transplant,

8 (30.8)

2 (7.7)

1 (3.8)

0 (0.0)

1 (3.8)

0 (0.0)

12 (46.2)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

63 (78.8)

12 (15.0)

2 (2.5)

3 (3.8)

6 (7.5)

2 (2.5)

65 (81.3)

11 (13.8)

9 (11.3)

1 (1.3)

1 (1.3)

OAD3s prescribed prior to commencing insulin, mean (SD)

0.1 (0.4)

2.2 (0.9)

Patients reporting prior hypoglycaemia, N (%)

18 (69.2)

21 (26.3)

Prior treatment regimens, N (%)

N = 26

N = 80

Insulin naïve

5 (19.2)

48 (60.0)

OAD

2 (7.7)

76 (95.0)

NPH4

3 (11.5)

17 (21.3)

Basal bolus

16 (61.5)

7 (8.8)

Premixed

3 (11.5)

8 (10.0)

Reasons to switch to glargine, N(%)

N = 26

N = 80

Hypoglycaemia

13 (50.0)

14 (17.5)

Uncontrolled HbA1c5

12 (46.2)

65 (81.3)

Convenience

1 (3.8)

0 (-)

Others

0 (-)

1 (0.0)